3个德国机构缔结了推动创新的放射性药物癌症治疗的框架协定。 3 German institutions formed a framework agreement to advance innovative radiopharmaceutical cancer treatments.

IMT、TUM和TUM大学医院已订立了一项框架协定,以加强创新的癌症放射药物治疗。 ITM, TUM, and TUM University Hospital have established a framework agreement to enhance innovative radiopharmaceutical treatments for cancer. 这一协作结合了IMT生产医疗放射性同位素、TUM核物理研究以及TUM医院的临床专门知识。 This collaboration combines ITM's production of medical radioisotopes, TUM's research in nuclear physics, and TUM Hospital's clinical expertise. 目标是加快核医学项目,扩大定向放射药品的供应,最终改善癌症患者的治疗结果。 The goal is to expedite nuclear medicine projects and broaden the availability of targeted radiopharmaceuticals, ultimately improving outcomes for cancer patients.